Levetiracetam (All indications)

Extremely preterm (< 28 weeks)

R analysis
id Study   Lib. in paper Exposition period    Study type 
 Control type 
 
Tags OR 95%CI x1/n1 x0/n0 no cases no exposed ROB Ref.
S12618
R47570		 Van Marter (Levetiracetam) (Controls unexposed, disease free), 2021 Prematurity - Extreme (<28 wk gestational age) at least 1st trimester prospective cohort unexposed, disease free excluded Adjustment: No 1.09 [0.07;17.73] C
excluded (control group) 		1/97   1/106 2 97
ref
S12615
R47552		 Van Marter (Levetiracetam) (Controls unexposed, sick), 2021 Prematurity - Extreme (<28 wk gestational age) at least 1st trimester prospective cohort unexposed, sick Adjustment: No 0.46 [0.02;11.72] C 1/97   0/15 1 97
ref
S9020
R30704		 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 Gestational age at birth (22-26 WA) during pregnancy (anytime or not specified) retrospective cohort (claims database) unexposed (general population or NOS) Adjustment: No 1.35 [0.19;9.60] C 1/621   2,041/1,710,441 2,042 621
ref
Total 2 studies 1.01 [0.19;5.41] 2,043 718
x1: number of endpoints among exposed, n1: number of exposed; x0: number of endpoints among non exposed, n0: number of non exposed; C: calculated odds ratio from numbers of events and effectives

Forest plot

StudyTE95% CIn casesn exposedweightROBABCDEF Van Marter (Levetiracetam) (Controls unexposed, sick), 2021Van Marter, 2021 1 0.46[0.02; 11.72]19727%ROB confusion: criticalROB selection: lowROB classification: lowROB missing: lowROB mesure: moderateROB reporting: low Coste (Levetiracetam) (Controls unexposed, NOS), 2020Coste, 2020 2 1.35[0.19; 9.60]2,04262173%ROB confusion: NAROB selection: NAROB classification: NAROB missing: NAROB mesure: NAROB reporting: NA Total (2 studies) I2 = 0% 1.01[0.19; 5.41]2,0437180.25.01.0ROB: A: confusion, B: selection, C: classification, D: missing, E: measurement, F: reportinglow,moderate,serious,critical,unclear,

1: Levetiracetam) (Controls unexposed, sick; 2: Levetiracetam) (Controls unexposed, NOS;

Sensitivity analysis

SubsetTE95% CIn casesn exposedkI2 Type of studies cohort studiescohort studies 1.01[0.19; 5.41]2,0437180%NAVan Marter (Levetiracetam) (Controls unexposed, sick), 2021 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 2 case control studiescase control studies 0 Type of controls unexposed (disease free or unspecified)unexposed (disease free or unspecified) 1.35[0.19; 9.60]2,042621 -NACoste (Levetiracetam) (Controls unexposed, NOS), 2020 1 unexposed, sickunexposed, sick 0.46[0.02; 11.72]197 -NAVan Marter (Levetiracetam) (Controls unexposed, sick), 2021 1 Tags Adjustment   - No  - No 1.01[0.19; 5.41]2,0437180%NAVan Marter (Levetiracetam) (Controls unexposed, sick), 2021 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 2 All studiesAll studies 1.01[0.19; 5.41]2,0437180%NAVan Marter (Levetiracetam) (Controls unexposed, sick), 2021 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 20.25.01.0

Publication bias and p-hacking diagnosis

funnel plot

Funnel plot not drawn. Less than 3 points.

Asymetry test p-value = NaN (by Egger's regression)

not enought points

p values plot

Funnel plot not drawn. Less than 3 points.

Sub-groups analysis using all included studies

excluded 12618

Sub-groupsTE95% CIn casesn exposedkI2ROB type of controls unexposed controls (disease free or unspecified)unexposed controls (disease free or unspecified) 1.26[0.25; 6.26]2,0447180%NAVan Marter (Levetiracetam) (Controls unexposed, disease free), 2021 Coste (Levetiracetam) (Controls unexposed, NOS), 2020 2 unexposed, sick controlsunexposed, sick controls Out of scale0.46[0.02; 11.72]197 -NAVan Marter (Levetiracetam) (Controls unexposed, sick), 2021 10.510.01.0